Fludroxycortide 0.0125% cream

Šalis: Didžioji Britanija

kalba: anglų

Šaltinis: MHRA (Medicines & Healthcare Products Regulatory Agency)

Veiklioji medžiaga:

Fludroxycortide

Prieinama:

Alliance Healthcare (Distribution) Ltd

ATC kodas:

D07AC07

INN (Tarptautinis Pavadinimas):

Fludroxycortide

Dozė:

125microgram/1gram

Vaisto forma:

Cutaneous cream

Vartojimo būdas:

Cutaneous

Klasė:

No Controlled Drug Status

Recepto tipas:

Valid as a prescribable product

Produkto santrauka:

BNF: 13040000

Pakuotės lapelis

_Colours_
_(Printed)_
_Title:_
_Ref:_
_Date:_
_Size (mm):_
_Modified:_
Fludroxycortide 0.0125% Cream
FC/TY/PIL
08/11/15
148(W) x 300(H)
27/03/19
_Colours_
_(Non printed)_
PROCESS
BLACK
REFERENCE
TRIM
PACKAGE LEAFLET: INFORMATION FOR THE USER
FLUDROXYCORTIDE 0.0125% W/W CREAM
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
KEEP THIS LEAFLET. YOU MAY NEED TO READ IT AGAIN.
-
IF YOU HAVE ANY FURTHER QUESTIONS, ASK YOUR DOCTOR OR PHARMACIST.
-
THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU ONLY. DO NOT PASS IT ON TO
OTHERS. IT MAY HARM THEM,
EVEN IF THEIR SIGNS OF ILLNESS ARE THE SAME AS YOURS.
-
IF YOU GET ANY SIDE EFFECTS, TALK TO YOUR DOCTOR OR PHARMACIST. THIS
INCLUDES ANY POSSIBLE SIDE
EFFECTS NOT LISTED IN THIS LEAFLET. SEE SECTION 4.
WHAT IS IN THIS LEAFLET:
1. What Fludroxycortide 0.0125% w/w Cream is and what it is used for
2. What you need to know before you use Fludroxycortide 0.0125% w/w
Cream
3. How to use Fludroxycortide 0.0125% w/w Cream
4. Possible side effects
5. How to store Fludroxycortide 0.0125% w/w Cream
6. Contents of the pack and other information 1. WHAT FLUDROXYCORTIDE 0.0125% W/W CREAM IS AND WHAT IT IS USED FOR
Fludroxycortide 0.0125% w/w Cream is a white cream for application to
the skin. Fludroxycortide
0.0125% w/w Cream belongs to a group of medicines called topical
steroids and is used to treat skin
conditions such as eczema and dermatitis of all types, especially when
the skin is moist or weeping.
Fludroxycortide 0.0125% w/w Cream can be used in adults and children. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE FLUDROXYCORTIDE 0.0125% W/W
CREAM
DO NOT USE FLUDROXYCORTIDE 0.0125% W/W CREAM
• for skin tuberculosis.
• for rosacea of the face.
• for acne.
• for dermatitis around the mouth.
• for itchiness of the genitals or anus.
• for skin conditions in babies including eczema or napkin rash.
•
for bacterial skin infections such as impetigo.
• for viral skin infections such as cold sores.
• for fungal ski

Prekės savybės

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Haelan Cream
Fludroxycortide 0.0125% w/w Cream
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Fludroxycortide 0.0125% w/w.
Excipients with known effect
Cetyl alcohol and propylene glycol
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Cream for topical administration
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Adults and children: Eczema and dermatitis of all types including
childhood and adult
atopic eczema, photodermatitis, primary irritant and allergic
dermatitis, lichen planus,
lichen simplex, prurigo nodularis, discoid lupus erythematosus,
necrobiosis lipoidica,
pretibial myxoedema and erthroderma.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
For moist, weeping lesions, the cream should be applied gently to the
affected area
two or three times daily.
Method of administration
The elderly: As the skin is likely to be thin, apply sparingly to
avoid development of
atrophy.
Dilution is not recommended, but if considered necessary, aqueous
cream BP may be
used.
4.3
CONTRAINDICATIONS
Tuberculosis of the skin, facial rosacea, acne vulgaris, perioral
dermatitis, perianal
and genital pruritus, dermatoses in infancy including eczema,
dermatitic napkin
eruption, bacterial (impetigo), viral (herpes simplex) and fungal
(candida or
dermatophyte) infections.
Hypersensitivity to the active substance or to any of the excipients
listed in section
6.1.
4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Preparations of Haelan are not intended for ophthalmic use.
Local and systemic toxicity is common especially following long-term
continuous
use, continued use on large areas of damaged skin, flexures and with
polythene
occlusion.
Systemic absorption of topical corticosteroids has produced reversible
hypothalamic-pituitary-adrenal (HPA) axis suppression (see section
4.8).
Therefore, patients receiving a large dose of a potent topical steroid
applied to a
large surface area or under an occlusive dressing should be evaluated
periodicall